GLOW Blend (BPC-157 + TB-500 + GHK-Cu) vs KPV
GLOW Blend (BPC-157 + TB-500 + GHK-Cu) (Multi-component research blend) and KPV (Alpha-MSH-derived tripeptide fragment) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | GLOW Blend (BPC-157 + TB-500 + GHK-Cu) | KPV |
|---|---|---|
| Compound class | Multi-component research blend | Alpha-MSH-derived tripeptide fragment |
| Research category | Cosmetic & Dermal | Healing & Recovery |
| Length (amino acids) | Not documented | 3 amino acids |
| Molecular weight | Not documented | 342.43 g/mol |
| Half-life | Not documented | Not documented |
| Origin | GLOW is a marketed research blend combining BPC-157, TB-500, and GHK-Cu. It is not a naturally occurring substance and exists only as a formulated combination whose exact composition may vary by supplier. | KPV is a synthetic tripeptide corresponding to the C-terminal three amino acids (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring melanocortin peptide. It is studied as a fragment that retains some anti-inflammatory properties of the parent hormone. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How GLOW Blend (BPC-157 + TB-500 + GHK-Cu) works
As a blend, GLOW combines the documented properties of its components: BPC-157's angiogenesis and growth-factor-related repair signaling, TB-500's actin regulation and cell-migration activity, and GHK-Cu's copper-delivery and extracellular-matrix remodeling signaling. These properties derive from separate preclinical and cosmetic research; the combined formulation itself is not validated in controlled human trials.
How KPV works
KPV is reported in preclinical studies to exert anti-inflammatory effects, and research has explored both melanocortin-receptor-dependent signaling and intracellular actions independent of classic MSH pigmentation activity. It has been studied for downregulation of pro-inflammatory signaling such as NF-kB-associated pathways in cell and animal models of colitis. These findings derive from in-vitro and rodent research.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
KPV
What sets each apart
GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
GLOW is oriented toward combined skin and tissue-repair research, adding the copper tripeptide GHK-Cu to the BPC-157/TB-500 pairing found in simpler blends.
KPV
KPV is distinguished by its melanocortin-pathway anti-inflammatory focus, in contrast to the antimicrobial LL-37 or the tissue-repair emphasis of BPC-157 and TB-500.
Frequently asked questions
How does GLOW differ from KLOW?
GLOW is BPC-157 + TB-500 + GHK-Cu. KLOW adds a fourth component, KPV (an anti-inflammatory alpha-MSH fragment), to the same three, so KLOW is essentially GLOW plus KPV. Both are studied in tissue-repair and skin-quality contexts.
What is the GLOW blend?
The GLOW blend is a research-peptide combination of BPC-157, TB-500, and GHK-Cu. Each component targets a different aspect of tissue and skin remodeling, and the blend is studied together rather than as a single approved drug.
What does each component contribute?
In research framing, BPC-157 is associated with angiogenesis (new blood-vessel growth) at injury sites, TB-500 with actin regulation and migration of repair cells, and GHK-Cu with copper delivery and collagen/elastin matrix remodeling. The rationale is complementary, non-overlapping mechanisms.
What is KPV?
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanocortin) effects. It is studied as a small anti-inflammatory peptide rather than as an approved therapeutic.
What is KPV studied for?
Preclinical research examines KPV for anti-inflammatory effects, particularly in models of intestinal inflammation and colitis, as well as skin inflammation. It is reported to enter cells and inhibit NF-kB signaling and pro-inflammatory cytokine production, and it can be transported into intestinal cells via the PepT1 transporter. No human clinical trials have confirmed these effects.
How does KPV produce anti-inflammatory effects without affecting pigmentation?
KPV corresponds only to the C-terminal tripeptide of alpha-MSH, so it preserves the anti-inflammatory activity associated with that region while omitting the sequence needed to activate melanocortin receptors that drive pigmentation. Mechanistically it is described as acting intracellularly on the NF-kB pathway, including inhibition of IkB kinase.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.